Table 1 Baseline characteristics
Total | Non LC | LC | |||
|---|---|---|---|---|---|
NAFLD | ALD | C–CH | |||
n | 122 | 62 | 17 | 3 | 19 |
Age (years) | 58.5 ± 13.9 | 55.9 ± 15.4 | 60.1 ± 10.9 | 53.6 ± 14.8 | 66.4 ± 8.7 |
Sex (male/female) | 93/29 | 48/14 | 16/1 | 0/3 | 13/6 |
Duration of diabetes (years) | 9.2 ± 7.5 | 8.0 ± 5.6 | 9.0 ± 6.9 | 10.3 ± 9.5 | 9.0 ± 4.8 |
BMI (kg/m2) | 26.9 ± 5.4 | 28.0 ± 5.3 | 26.8 ± 5.4 | 29.3 ± 15.8 | 23.9 ± 2.8 |
Platelet (×104/μL) | 18.3 ± 6.5 | 20.3 ± 5.7 | 19.0 ± 4.6 | 20.5 ± 6.6 | 9.3 ± 4.0 |
HbA1c (%) | 8.48 ± 1.43 | 8.57 ± 1.23 | 8.29 ± 1.77 | 9.76 ± 2.70 | 8.12 ± 1.29 |
AST (IU/L) | 56.0 ± 25.8 | 52.7 ± 25.3 | 66.5 ± 28.3 | 71.0 ± 26.2 | 60.4 ± 30.9 |
ALT (IU/L) | 75.1 ± 45.2 | 79.2 ± 45.4 | 88.0 ± 67.4 | 94.0 ± 10.8 | 49.5 ± 28.4 |
γGT (IU/L) | 155.2 ± 161.1 | 112.0 ± 80.4 | 232.8 ± 144.7 | 92.3 ± 47.4 | 277.6 ± 310.4 |
Duration of sitagliptin dosing (months) | 13.7 ± 10.1 | 15.2 ± 10.0 | 10.6 ± 9.1 | 7.3 ± 6.6 | 9.1 ± 9.6 |